In connection with the start of the phase 3 trials of PCV21, Sanofi has expanded its alliance with South Korea-based SK Bio, ...

Artificial intelligence, machine learning models, automation, connected devices, cloud data storage, intuitive study ...

Preliminary results from TROPION-Lung05 reported at the main ESMO congress last year revealed an overall response rate (ORR) ...

The task ahead of Vertex now is to migrate patients already on Trikafta to the new drug. That is supported by data from the ...

The 2024 American College of Rheumatology (ACR) annual meeting spotlighted transformative advancements in cell therapies for ...

At ASCO, the stellar PFS data sparked speculation that Tagrisso will become the standard of care in this type of early lung ...

Quality compliance in the pharma industry is foundational to guaranteeing safe and effective products. For years, Good ...

Pfizer has partnered with a ‘computation-driven’ pharmaceutical technology company to develop a drug discovery platform powered by artificial intelligence (AI). Its collaboration with ...

The pharmaceutical industry operates under a complex regulatory landscape, balancing government oversight with self-imposed standards. Ben Hargreaves finds that the ABPI recently updated its code ...

Antibody-drug conjugates remain front and centre of the biopharma world. Following Enhertu’s historic agnostic approval in HER2-positive solid tumours and TIVDAK winning full approval, the field ...

The outlook for drug development to treat rare diseases looks encouraging, offering hope to the 300 million people globally facing the significant challenges of these often-overlooked conditions.

A federal appeals court in the US has declined to overturn an attempt by Novartis to block the launch of a generic version of its blockbuster heart failure drug Entresto. The US Court of Appeals ...